Whilst Sanofi offers recombinant antigens, GSK will provide pandemic adjuvant, both of which have proven to be successful against influenza. Both of them have received the go-ahead of conducting their Phase 3 clinical study in India. The purpose of this study is to determine the safety, efficacy and other critical components that this covid vaccine can provide.
The study will be conducted on an international, random and double-blinded method, with over 35000, 18 years or older candidates across a spectrum of nations that include the USA, Africa, Asia and Latin America. Participants including those in the control group will be offered the study vaccine after it is determined to be safe as well as effective, claimed Sanofi.
Annapurna Das, country head of Sanofi Pasteur India mentioned that India is participating in the Phase 3 trials, depending on certain approvals. The company is expected to commence enrollment in the study soon. Continuous research and development in the domain of vaccination become the need of the hour since the virus is constantly evolving.
The purpose of conducting this study is not just to curtail the COVID symptoms in adults, but also to prevent severe cases, asymptomatic infection and loss of life. According to other studies, antibodies that are created against the Beta variant, largely hold their ground against some of the other variants as well. The said study also looks to understand how the candidates will react to other variants too. Both the said companies look to complement each other to offer a plethora of advantages. One of these includes temperature which has been a major bone of contention for a large number of developing countries. Through this, not only will it become easy to implement, but also distribute the vaccine internationally through the available infrastructure of refrigerators.
This vaccine candidate is curated to high as well as regular immune systems and stop future transmission.
Share
Tweet
